Martin S Weber

Summary

Affiliation: Klinikum rechts der Isar
Country: Germany

Publications

  1. ncbi request reprint Current treatment strategies for multiple sclerosis - efficacy versus neurological adverse effects
    Martin S Weber
    Department of Neurology, Technische Universitat Munchen, Munich, Germany
    Curr Pharm Des 18:209-19. 2012
  2. pmc IgG glycan hydrolysis by EndoS inhibits experimental autoimmune encephalomyelitis
    Mahdia Benkhoucha
    Department of Pathology and Immunology, University of Geneva, 1211, Geneva, Switzerland
    J Neuroinflammation 9:209. 2012
  3. pmc Repetitive pertussis toxin promotes development of regulatory T cells and prevents central nervous system autoimmune disease
    Martin S Weber
    Department of Neurology, Technische Universitat Munchen, Munich, Germany
    PLoS ONE 5:e16009. 2010
  4. doi request reprint Developmental maturation of innate immune cell function correlates with susceptibility to central nervous system autoimmunity
    Deetje Hertzenberg
    Department of Neurology, Technische Universitat Munchen, Munich, Germany
    Eur J Immunol 43:2078-88. 2013
  5. doi request reprint Favourable response to plasma exchange in tumefactive CNS demyelination with delayed B-cell response
    Christian L Seifert
    Department of Neurology, Klinikum rechts der Isar, Technische Universitat Munchen, Munchen, Germany
    Mult Scler 18:1045-9. 2012
  6. doi request reprint The combination of interferon-beta and HMG-CoA reductase inhibition in multiple sclerosis: enthusiasm lost too soon?
    Johann Sellner
    Department of Neurology, Klinikum rechts der Isar, Technische Universitat Munchen, Munchen, Germany
    CNS Neurosci Ther 16:362-73. 2010
  7. pmc CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation
    Markus C Kowarik
    Department of Neurology, Klinikum rechts der Isar, Technische Universitat Munchen, 81675 Munich, Germany
    J Neuroinflammation 9:93. 2012
  8. pmc Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders
    Klaus Lehmann-Horn
    Department of Neurology, Technische Universitat Munchen, Munich, Germany
    J Neuroinflammation 8:146. 2011
  9. doi request reprint Disease-modifying agents for multiple sclerosis: recent advances and future prospects
    Til Menge
    Department of Neurology, Heinrich Heine University, Dusseldorf, Germany
    Drugs 68:2445-68. 2008
  10. doi request reprint The role of antibodies in multiple sclerosis
    Martin S Weber
    Department of Neurology, Technische Universität Müchen, Munich, Germany
    Biochim Biophys Acta 1812:239-45. 2011

Collaborators

Detail Information

Publications13

  1. ncbi request reprint Current treatment strategies for multiple sclerosis - efficacy versus neurological adverse effects
    Martin S Weber
    Department of Neurology, Technische Universitat Munchen, Munich, Germany
    Curr Pharm Des 18:209-19. 2012
    ..In this review, we aim to critically evaluate the risk/benefit ratio of therapeutic strategies in treatment of MS with a specific focus on infectious neurological side effects...
  2. pmc IgG glycan hydrolysis by EndoS inhibits experimental autoimmune encephalomyelitis
    Mahdia Benkhoucha
    Department of Pathology and Immunology, University of Geneva, 1211, Geneva, Switzerland
    J Neuroinflammation 9:209. 2012
    ..These results identify EndoS as a potential therapeutic agent against antibody-mediated CNS autoimmune disorders...
  3. pmc Repetitive pertussis toxin promotes development of regulatory T cells and prevents central nervous system autoimmune disease
    Martin S Weber
    Department of Neurology, Technische Universitat Munchen, Munich, Germany
    PLoS ONE 5:e16009. 2010
    ..Besides its therapeutic implication, this finding suggests that encounter of the immune system with microbial products may not only be part of CNS autoimmune disease pathogenesis but also of its regulation...
  4. doi request reprint Developmental maturation of innate immune cell function correlates with susceptibility to central nervous system autoimmunity
    Deetje Hertzenberg
    Department of Neurology, Technische Universitat Munchen, Munich, Germany
    Eur J Immunol 43:2078-88. 2013
    ..Collectively, these findings indicate that the innate immune compartment functionally matures during development, which may be a prerequisite for development of T-cell-mediated CNS autoimmune disease. ..
  5. doi request reprint Favourable response to plasma exchange in tumefactive CNS demyelination with delayed B-cell response
    Christian L Seifert
    Department of Neurology, Klinikum rechts der Isar, Technische Universitat Munchen, Munchen, Germany
    Mult Scler 18:1045-9. 2012
    ..This delay in the development of a humoral immune response may reflect the step-wise B-cell colonization of the CNS and represent an attractive therapeutic window of opportunity...
  6. doi request reprint The combination of interferon-beta and HMG-CoA reductase inhibition in multiple sclerosis: enthusiasm lost too soon?
    Johann Sellner
    Department of Neurology, Klinikum rechts der Isar, Technische Universitat Munchen, Munchen, Germany
    CNS Neurosci Ther 16:362-73. 2010
    ..Moreover, we try to address the evident question whether usage of this combination routinely requires caution, since the number of IFN-β-treated MS patients receiving statins for lowering of cholesterol is expected to grow...
  7. pmc CXCL13 is the major determinant for B cell recruitment to the CSF during neuroinflammation
    Markus C Kowarik
    Department of Neurology, Klinikum rechts der Isar, Technische Universitat Munchen, 81675 Munich, Germany
    J Neuroinflammation 9:93. 2012
    ....
  8. pmc Anti-CD20 B-cell depletion enhances monocyte reactivity in neuroimmunological disorders
    Klaus Lehmann-Horn
    Department of Neurology, Technische Universitat Munchen, Munich, Germany
    J Neuroinflammation 8:146. 2011
    ..We elucidated the regulatory role of un-activated B-cells in EAE and investigated whether anti-CD20 may collaterally diminish regulatory B-cell properties in treatment of neuroimmunological disorders...
  9. doi request reprint Disease-modifying agents for multiple sclerosis: recent advances and future prospects
    Til Menge
    Department of Neurology, Heinrich Heine University, Dusseldorf, Germany
    Drugs 68:2445-68. 2008
    ..Finally, with the advent of these highly potent novel therapies, rare, but potentially serious adverse effects have been noted, namely infections and malignancies. These are critically reviewed and put into perspective...
  10. doi request reprint The role of antibodies in multiple sclerosis
    Martin S Weber
    Department of Neurology, Technische Universität Müchen, Munich, Germany
    Biochim Biophys Acta 1812:239-45. 2011
    ....
  11. doi request reprint Cooperation of B cells and T cells in the pathogenesis of multiple sclerosis
    Martin S Weber
    Department of Neurology, Technische Universitat Munchen, Ismaningerstrasse 22, 81675, Munich, Germany
    Results Probl Cell Differ 51:115-26. 2010
    ..Taken together, B cells and T cells thus closely support one another to participate in the pathogenesis of MS in an inflammatory but also in a regulatory manner...
  12. pmc Targeting B cells in the treatment of multiple sclerosis: recent advances and remaining challenges
    Klaus Lehmann-Horn
    Department of Neurology, Technische Universitat Munchen, Munich, Germany
    Ther Adv Neurol Disord 6:161-73. 2013
    ....
  13. doi request reprint The value of the serum neurofilament protein heavy chain as a biomarker for peri-operative brain injury after carotid endarterectomy
    Johann Sellner
    Department of Neurology, Klinikum rechts der Isar, Technische Universitat Munchen, Munich, Germany
    Neurochem Res 34:1969-74. 2009
    ....